{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:21Z","timestamp":1793505441836,"version":"4.5.0"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.prp.2025.156036","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:59:28Z","timestamp":1748239168000},"page":"156036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies"],"prefix":"10.1016","volume":"271","author":[{"given":"Sneha","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-2022","authenticated-orcid":false,"given":"Shaktipal","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrapali","family":"Mhaiskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156036_bib1","doi-asserted-by":"crossref","unstructured":"Siegel, R.L., K.D. Miller, and A.J.Cacjfc Jemal, Cancer statistics, 2019. 2019. 69(1): p. 7-34.","DOI":"10.3322\/caac.21551"},{"key":"10.1016\/j.prp.2025.156036_bib2","article-title":"Clinicopathological differences in MYC and BCL2 protein expression between primary extranodal and nodal diffuse large B-cell lymphoma","volume":"260","author":"Sasaki","year":"2024","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156036_bib3","first-page":"1","article-title":"How we treat mature B-cell neoplasms (indolent B-cell lymphomas)","volume":"14","author":"Lumish","year":"2021"},{"key":"10.1016\/j.prp.2025.156036_bib4","series-title":"Seminars in hematology","article-title":"Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results","author":"Younes","year":"2016"},{"key":"10.1016\/j.prp.2025.156036_bib5","doi-asserted-by":"crossref","unstructured":"Susanibar-Adaniya, S. and S.K.J.Ajoh Barta, 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. 2021. 96(5): p. 617-629.","DOI":"10.1002\/ajh.26151"},{"key":"10.1016\/j.prp.2025.156036_bib6","doi-asserted-by":"crossref","unstructured":"Khanmohammadi, S., et al., MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. 2025. 8(1): p. e70070.","DOI":"10.1002\/cnr2.70070"},{"key":"10.1016\/j.prp.2025.156036_bib7","doi-asserted-by":"crossref","unstructured":"Ferry, J.A., et al., Mature B, T and NK-cell, plasma cell and histiocytic\/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification. 2024. 17(1): p. 51.","DOI":"10.1186\/s13045-024-01570-5"},{"key":"10.1016\/j.prp.2025.156036_bib8","doi-asserted-by":"crossref","unstructured":"Swerdlow, S.H., et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms. 2016. 127(20): p. 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"issue":"11","key":"10.1016\/j.prp.2025.156036_bib9","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ajh.27075","article-title":"2024 Update: Advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.prp.2025.156036_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.prp.2017.02.012","article-title":"Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6","volume":"213","author":"Li","year":"2017","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156036_bib11","article-title":"The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: a retrospective cohort study in China","volume":"233","author":"Nong","year":"2022","journal-title":"Pathol. Res Pr."},{"issue":"10","key":"10.1016\/j.prp.2025.156036_bib12","article-title":"Molecular classification and therapeutics in diffuse large B-cell lymphoma","volume":"3","author":"Shimkus","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib13","article-title":"Exames laboratoriais complementares indicados no apoio ao diagn\u00f3stico do Linfoma Difuso de Grandes C\u00e9lulas B (LDGCB)","volume":"33","author":"dos Santos Guilherme","year":"2008","journal-title":"Arq. Bras. De. Ci\u00eancias da Sa\u00faDe."},{"issue":"15","key":"10.1016\/j.prp.2025.156036_bib14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156036_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5581\/1516-8484.20120111","article-title":"Pathophysiology and molecular aspects of diffuse large B-cell lymphoma","volume":"34","author":"Gouveia","year":"2012","journal-title":"Rev. Bras. De. Hematol. e Hemoter."},{"key":"10.1016\/j.prp.2025.156036_bib16","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.156036_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.prp.2025.156036_bib18","first-page":"4916","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib19","first-page":"1","article-title":"Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review","volume":"16","author":"Berhan","year":"2025","journal-title":"Discov. Oncol."},{"issue":"40","key":"10.1016\/j.prp.2025.156036_bib20","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","article-title":"Mechanisms of chromosomal translocations in B cell lymphomas","volume":"20","author":"K\u00fcppers","year":"2001","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","article-title":"Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell\u2013like diffuse large B cell lymphoma","volume":"204","author":"Lenz","year":"2007","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.prp.2025.156036_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cell.2004.08.006","article-title":"AID is required for c-myc\/IgH chromosome translocations in vivo","volume":"118","author":"Ramiro","year":"2004","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng.2007.35","article-title":"AID is required for germinal center\u2013derived lymphomagenesis","volume":"40","author":"Pasqualucci","year":"2008","journal-title":"Nat. Genet."},{"issue":"6844","key":"10.1016\/j.prp.2025.156036_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.prp.2025.156036_bib25","series-title":"Burkitt\u2019s Lymphoma","first-page":"151","article-title":"Diffuse Large B-Cell Lymphoma","author":"Pasqualucci","year":"2012"},{"issue":"23","key":"10.1016\/j.prp.2025.156036_bib26","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.232581199","article-title":"Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas","volume":"99","author":"Wang","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.prp.2025.156036_bib27","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation","volume":"103","author":"Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"issue":"7337","key":"10.1016\/j.prp.2025.156036_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.prp.2025.156036_bib29","series-title":"Seminars in diagnostic pathology","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","author":"Schneider","year":"2011"},{"key":"10.1016\/j.prp.2025.156036_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102510","article-title":"Management of indolent B-cell lymphomas: A review of approved and emerging targeted therapies","volume":"113","author":"Smyth","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.prp.2025.156036_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101463","article-title":"Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults","volume":"36","author":"Goldman","year":"2023","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.prp.2025.156036_bib32","article-title":"Polyamine catabolism is concentrated in tumor-associated histiocytes in diffuse large B-cell lymphoma and classic Hodgkin lymphoma","volume":"248","author":"Bronson","year":"2023","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156036_bib33","doi-asserted-by":"crossref","unstructured":"D\u00f6hner, H., et al., Genomic aberrations and survival in chronic lymphocytic leukemia. 2000. 343(26): p. 1910-1916.","DOI":"10.1056\/NEJM200012283432602"},{"issue":"6","key":"10.1016\/j.prp.2025.156036_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib35","volume":"2","author":"Swerdlow","year":"2008"},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib36","first-page":"320","volume":"52","author":"Zapatka","year":"2020","journal-title":"Landsc. Viral Assoc. Hum. Cancers"},{"issue":"10","key":"10.1016\/j.prp.2025.156036_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.prp.2025.156036_bib38","first-page":"221","article-title":"Viral entry","volume":"391","author":"Chesnokova","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"10.1016\/j.prp.2025.156036_bib39","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson, D.A., et al., The pathogenesis of Epstein\u2013Barr virus persistent infection. 2013. 3(3): p. 227-232.","DOI":"10.1016\/j.coviro.2013.04.005"},{"issue":"12","key":"10.1016\/j.prp.2025.156036_bib40","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.prp.2025.156036_bib41","doi-asserted-by":"crossref","unstructured":"Katsuyoshi, T.J.Jo.C. and E. Hematopathology, Highlights: Follicular Lymphoma. 2023. 63(4): p. 212-213.","DOI":"10.3960\/jslrt.23051"},{"issue":"4","key":"10.1016\/j.prp.2025.156036_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156036_bib43","doi-asserted-by":"crossref","unstructured":"Egle, A., et al., VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. 2004. 103(6): p. 2276-2283.","DOI":"10.1182\/blood-2003-07-2469"},{"key":"10.1016\/j.prp.2025.156036_bib44","doi-asserted-by":"crossref","unstructured":"Bonzheim, I., et al., A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma. 2011. 118(12): p. 3442-3444.","DOI":"10.1182\/blood-2011-07-368944"},{"key":"10.1016\/j.prp.2025.156036_bib45","series-title":"Seminars in Oncology","article-title":"New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs","author":"Devan","year":"2018"},{"key":"10.1016\/j.prp.2025.156036_bib46","doi-asserted-by":"crossref","unstructured":"Mozas, P., et al., Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors. 2023. 41(4): p. 631-643.","DOI":"10.1002\/hon.3132"},{"key":"10.1016\/j.prp.2025.156036_bib47","doi-asserted-by":"crossref","unstructured":"Salaverria, I., O. Weigert, and L.J.B.A. Quintanilla-Martinez, The clinical and molecular taxonomy of t (14; 18)-negative follicular lymphomas. 2023. 7(18): p. 5258-5271.","DOI":"10.1182\/bloodadvances.2022009456"},{"key":"10.1016\/j.prp.2025.156036_bib48","doi-asserted-by":"crossref","unstructured":"McLachlan, T., et al., B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers. 2022. 20(12): p. 1711-1723.","DOI":"10.1158\/1541-7786.MCR-22-0567"},{"issue":"7","key":"10.1016\/j.prp.2025.156036_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.prp.2025.156036_bib50","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1111\/febs.13624","article-title":"The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane","volume":"283","author":"Luna-Vargas","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.prp.2025.156036_bib51","doi-asserted-by":"crossref","unstructured":"Qian, S., et al., The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. 2022. 12: p. 985363.","DOI":"10.3389\/fonc.2022.985363"},{"issue":"6","key":"10.1016\/j.prp.2025.156036_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041046","article-title":"The mitochondrial pathway of apoptosis Part II: The BCL-2 protein family","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"10.1016\/j.prp.2025.156036_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1146\/annurev.ge.18.120184.003005","article-title":"The molecular genetics of cellular oncogenes","volume":"18","author":"Varmus","year":"1984","journal-title":"Annu Rev. Genet"},{"issue":"6064","key":"10.1016\/j.prp.2025.156036_bib54","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/320760a0","article-title":"Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment","volume":"320","author":"Coppola","year":"1986","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-024-01570-5","article-title":"Mature B, T and NK-cell, plasma cell and histiocytic\/dendritic cell neoplasms: classification according to the world health organization and international consensus classification","volume":"17","author":"Ferry","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2025.156036_bib56","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4161\/cc.8.8.8126","article-title":"Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?","volume":"8","author":"Leon","year":"2009","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.prp.2025.156036_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020523","article-title":"MYC's fine line between B cell development and malignancy","volume":"9","author":"de Barrios","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.prp.2025.156036_bib58","doi-asserted-by":"crossref","unstructured":"Vallespin\u00f3s, M., et al., B Lymphocyte commitment program is driven by the proto-oncogene c-Myc. 2011. 186(12): p. 6726-6736.","DOI":"10.4049\/jimmunol.1002753"},{"key":"10.1016\/j.prp.2025.156036_bib59","doi-asserted-by":"crossref","unstructured":"Klein, U., et al., Transcriptional analysis of the B cell germinal center reaction. 2003. 100(5): p. 2639-2644.","DOI":"10.1073\/pnas.0437996100"},{"key":"10.1016\/j.prp.2025.156036_bib60","doi-asserted-by":"crossref","unstructured":"Dominguez-Sola, D., et al., The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. 2012. 13(11): p. 1083-1091.","DOI":"10.1038\/ni.2428"},{"key":"10.1016\/j.prp.2025.156036_bib61","doi-asserted-by":"crossref","unstructured":"Nguyen, L., P. Papenhausen, and H.J.G. Shao, The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. 2017. 8(4): p. 116.","DOI":"10.3390\/genes8040116"},{"key":"10.1016\/j.prp.2025.156036_bib62","doi-asserted-by":"crossref","unstructured":"De Silva, N.S. and U.J.Nri Klein, Dynamics of B cells in germinal centres. 2015. 15(3): p. 137-148.","DOI":"10.1038\/nri3804"},{"key":"10.1016\/j.prp.2025.156036_bib63","doi-asserted-by":"crossref","unstructured":"Walker, S.R., et al., The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. 2015. 34(9): p. 1073-1082.","DOI":"10.1038\/onc.2014.61"},{"key":"10.1016\/j.prp.2025.156036_bib64","doi-asserted-by":"crossref","unstructured":"Saito, M., et al., BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. 2009. 106(27): p. 11294-11299.","DOI":"10.1073\/pnas.0903854106"},{"key":"10.1016\/j.prp.2025.156036_bib65","doi-asserted-by":"crossref","unstructured":"Cardenas, M.G., et al., The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. 2017. 23(4): p. 885-893.","DOI":"10.1158\/1078-0432.CCR-16-2071"},{"key":"10.1016\/j.prp.2025.156036_bib66","doi-asserted-by":"crossref","unstructured":"Burotto, M., A. Berkovits, and K.J.Eroh Dunleavy, Double hit lymphoma: from biology to therapeutic implications. 2016. 9(7): p. 669-678.","DOI":"10.1080\/17474086.2016.1182858"},{"key":"10.1016\/j.prp.2025.156036_bib67","article-title":"An updated review of a novel method for examining P53 mutations in different forms of cancer","volume":"248","author":"Shomali","year":"2023","journal-title":"Pathol. Res Pr."},{"issue":"20","key":"10.1016\/j.prp.2025.156036_bib68","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/jnci\/88.20.1442","article-title":"Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies","volume":"88","author":"Harris","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156036_bib70","doi-asserted-by":"crossref","unstructured":"Yu, L., et al., Emerging roles of the tumor suppressor p53 in metabolism. 2022. 9: p. 762742.","DOI":"10.3389\/fcell.2021.762742"},{"key":"10.1016\/j.prp.2025.156036_bib71","series-title":"Seminars in cancer biology","article-title":"Targeting p53 for the treatment of cancer","author":"Duffy","year":"2022"},{"key":"10.1016\/j.prp.2025.156036_bib72","doi-asserted-by":"crossref","unstructured":"Profit\u00f3s-Pelej\u00e0, N., et al., Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. 2022. 14(4): p. 860.","DOI":"10.3390\/cancers14040860"},{"key":"10.1016\/j.prp.2025.156036_bib73","doi-asserted-by":"crossref","unstructured":"Levit-Zerdoun, E., et al., Survival of Ig\u03b1-deficient mature B cells requires BAFF-R function. 2016. 196(5): p. 2348-2360.","DOI":"10.4049\/jimmunol.1501707"},{"key":"10.1016\/j.prp.2025.156036_bib74","doi-asserted-by":"crossref","unstructured":"Kraus, M., et al., Survival of resting mature B lymphocytes depends on BCR signaling via the Ig\u03b1\/\u03b2 heterodimer. 2004. 117(6): p. 787-800.","DOI":"10.1016\/j.cell.2004.05.014"},{"key":"10.1016\/j.prp.2025.156036_bib75","doi-asserted-by":"crossref","unstructured":"Schmid, V.K. and E.J.Fi.O. Hobeika, B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. 2024. 14: p. 1339620.","DOI":"10.3389\/fonc.2024.1339620"},{"key":"10.1016\/j.prp.2025.156036_bib76","doi-asserted-by":"crossref","unstructured":"Vervoordeldonk, M.Y., et al., B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy. 2024. 65(8): p. 1031-1043.","DOI":"10.1080\/10428194.2024.2341151"},{"key":"10.1016\/j.prp.2025.156036_bib77","doi-asserted-by":"crossref","unstructured":"Rodig, S.J., et al., TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. 2005. 29(2): p. 196-203.","DOI":"10.1097\/01.pas.0000149689.75462.ff"},{"key":"10.1016\/j.prp.2025.156036_bib78","doi-asserted-by":"crossref","unstructured":"Mathas, S., et al., Elevated NF-\u03baB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. 2005. 106(13): p. 4287-4293.","DOI":"10.1182\/blood-2004-09-3620"},{"key":"10.1016\/j.prp.2025.156036_bib79","doi-asserted-by":"crossref","unstructured":"de Oliveira, K.A., et al., A roadmap of constitutive NF-\u03baB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses. 2016. 8: p. 1-16.","DOI":"10.1186\/s13073-016-0280-5"},{"key":"10.1016\/j.prp.2025.156036_bib80","doi-asserted-by":"crossref","unstructured":"Ranuncolo, S.M., et al., Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. 2012. 120(18): p. 3756-3763.","DOI":"10.1182\/blood-2012-01-405951"},{"key":"10.1016\/j.prp.2025.156036_bib81","doi-asserted-by":"crossref","unstructured":"Pittaluga, S., et al., Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. 2020. 1(2): p. 155-161.","DOI":"10.1158\/2643-3230.BCD-20-0009"},{"key":"10.1016\/j.prp.2025.156036_bib82","doi-asserted-by":"crossref","unstructured":"Izban, K.F., et al., Characterization of NF-\u03baB expression in Hodgkin's disease: inhibition of constitutively expressed NF-\u03baB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. 2001. 14(4): p. 297-310.","DOI":"10.1038\/modpathol.3880306"},{"key":"10.1016\/j.prp.2025.156036_bib83","doi-asserted-by":"crossref","unstructured":"Gamboa-Cede\u00f1o, A.M., et al., Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. 2019. 145: p. 1437-1448.","DOI":"10.1007\/s00432-019-02909-z"},{"issue":"9","key":"10.1016\/j.prp.2025.156036_bib84","first-page":"2153","volume":"10","author":"Jardin","year":"2022","journal-title":"NFkB Pathw. Hodgkin Lymphoma"},{"key":"10.1016\/j.prp.2025.156036_bib85","doi-asserted-by":"crossref","unstructured":"Troutman, T.D., et al., Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine\/threonine kinases PI3K\/Akt. 2012. 109(1): p. 273-278.","DOI":"10.1073\/pnas.1118579109"},{"key":"10.1016\/j.prp.2025.156036_bib86","doi-asserted-by":"crossref","unstructured":"Castello, A., et al., Nck-mediated recruitment of BCAP to the BCR regulates the PI (3) K-Akt pathway in B cells. 2013. 14(9): p. 966-975.","DOI":"10.1038\/ni.2685"},{"key":"10.1016\/j.prp.2025.156036_bib87","doi-asserted-by":"crossref","unstructured":"Reif, K., et al., Cutting edge: differential roles for phosphoinositide 3-kinases, p110\u03b3 and p110\u03b4, in lymphocyte chemotaxis and homing. 2004. 173(4): p. 2236-2240.","DOI":"10.4049\/jimmunol.173.4.2236"},{"key":"10.1016\/j.prp.2025.156036_bib88","doi-asserted-by":"crossref","unstructured":"Alessi, D.R., et al., Mechanism of activation of protein kinase B by insulin and IGF-1. 1996. 15(23): p. 6541-6551.","DOI":"10.1002\/j.1460-2075.1996.tb01045.x"},{"key":"10.1016\/j.prp.2025.156036_bib89","doi-asserted-by":"crossref","unstructured":"Nocka, L.M., et al., Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2. 2023. 12: p. e82676.","DOI":"10.7554\/eLife.82676"},{"key":"10.1016\/j.prp.2025.156036_bib90","unstructured":"Buchner, M.J.F.L., Insights into PI3K\/AKT signaling in B cell development and chronic lymphocytic leukemia."},{"issue":"4","key":"10.1016\/j.prp.2025.156036_bib91","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large b cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"33","key":"10.1016\/j.prp.2025.156036_bib92","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib93","doi-asserted-by":"crossref","unstructured":"Luo, Y., et al., Signaling pathways of EBV-induced oncogenesis. 2021. 21(1): p. 93.","DOI":"10.1186\/s12935-021-01793-3"},{"key":"10.1016\/j.prp.2025.156036_bib94","doi-asserted-by":"crossref","unstructured":"Salunkhe, S. and T.J.M.I. Vaidya, CD40-miRNA axis controls prospective cell fate determinants during B cell differentiation. 2020. 126: p. 46-55.","DOI":"10.1016\/j.molimm.2020.07.007"},{"key":"10.1016\/j.prp.2025.156036_bib95","doi-asserted-by":"crossref","unstructured":"Drees, E.E. and D.M.J.Tic Pegtel, Circulating miRNAs as biomarkers in aggressive B cell lymphomas. 2020. 6(11): p. 910-923.","DOI":"10.1016\/j.trecan.2020.06.003"},{"key":"10.1016\/j.prp.2025.156036_bib96","doi-asserted-by":"crossref","unstructured":"Coffre, M. and S.B.J.Timm Koralov, miRNAs in B cell development and lymphomagenesis. 2017. 23(8): p. 721-736.","DOI":"10.1016\/j.molmed.2017.06.001"},{"key":"10.1016\/j.prp.2025.156036_bib97","doi-asserted-by":"crossref","unstructured":"Mohammadian, M., et al., B-Cell Chronic Lymphocytic Leukemia and B-Cell Lymphomas: The Key Role of Micro and Long Noncoding RNAs. 2024. 2024(1): p. 3091760.","DOI":"10.1155\/2024\/3091760"},{"key":"10.1016\/j.prp.2025.156036_bib98","doi-asserted-by":"crossref","unstructured":"Wang, W., et al., MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. 2012. 97(4): p. 586.","DOI":"10.3324\/haematol.2011.048132"},{"key":"10.1016\/j.prp.2025.156036_bib99","doi-asserted-by":"crossref","unstructured":"Lin, J., et al., Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. 2011. 25(1): p. 145-152.","DOI":"10.1038\/leu.2010.230"},{"key":"10.1016\/j.prp.2025.156036_bib100","doi-asserted-by":"crossref","unstructured":"Leich, E., et al., MicroRNA profiles of t (14; 18)\u2013negative follicular lymphoma support a late germinal center B-cell phenotype. 2011. 118(20): p. 5550-5558.","DOI":"10.1182\/blood-2011-06-361972"},{"key":"10.1016\/j.prp.2025.156036_bib101","doi-asserted-by":"crossref","unstructured":"Di Lisio, L., et al., The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. 2012. 120(9): p. 1782-1790.","DOI":"10.1182\/blood-2012-05-402784"},{"key":"10.1016\/j.prp.2025.156036_bib102","doi-asserted-by":"crossref","unstructured":"Balaj, L., et al., Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. 2011. 2(1): p. 180.","DOI":"10.1038\/ncomms1180"},{"issue":"13","key":"10.1016\/j.prp.2025.156036_bib103","first-page":"E1826","article-title":"Identification of tissue-specific cell death using methylation patterns of circulating","volume":"113","author":"Lehmann-Werman","year":"2016","journal-title":"DNA"},{"key":"10.1016\/j.prp.2025.156036_bib104","doi-asserted-by":"crossref","unstructured":"Mouliere, F., et al., Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. 2014. 8(5): p. 927-941.","DOI":"10.1016\/j.molonc.2014.02.005"},{"key":"10.1016\/j.prp.2025.156036_bib105","doi-asserted-by":"crossref","unstructured":"Burnham, P., et al., Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. 2016. 6(1): p. 27859.","DOI":"10.1038\/srep27859"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13402-018-0413-5","article-title":"Cell-free DNA in cancer: current insights","volume":"42","author":"Fettke","year":"2019","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.prp.2025.156036_bib107","doi-asserted-by":"crossref","unstructured":"Cui, Y., et al., Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas. 2021. 16(9): p. e0256979.","DOI":"10.1371\/journal.pone.0256979"},{"key":"10.1016\/j.prp.2025.156036_bib108","doi-asserted-by":"crossref","unstructured":"Maco, M., et al., Circulating tumor DNA in Hodgkin lymphoma. 2022. 101(11): p. 2393-2403.","DOI":"10.1007\/s00277-022-04949-x"},{"issue":"6769","key":"10.1016\/j.prp.2025.156036_bib109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.prp.2025.156036_bib110","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030675","article-title":"Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas","volume":"10","author":"Pileri","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(94)00343-J","article-title":"Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation","volume":"31","author":"Fuller","year":"1995","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.prp.2025.156036_bib113","doi-asserted-by":"crossref","unstructured":"Munck, J., et al., Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: Long-term results for 96 patients with tumors>\u20095 cm. 1996. 7(9): p. 925-931.","DOI":"10.1093\/oxfordjournals.annonc.a010795"},{"key":"10.1016\/j.prp.2025.156036_bib114","doi-asserted-by":"crossref","unstructured":"Freilone, R., et al., Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate-to high-grade non-Hodgkin's lymphoma. 1996. 7(9): p. 919-924.","DOI":"10.1093\/oxfordjournals.annonc.a010794"},{"issue":"6","key":"10.1016\/j.prp.2025.156036_bib115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"5-6","key":"10.1016\/j.prp.2025.156036_bib116","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/02841860310014435","article-title":"A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib117","doi-asserted-by":"crossref","unstructured":"Sengar, M., et al., Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. 2023. 200(4): p. 429-439.","DOI":"10.1111\/bjh.18532"},{"key":"10.1016\/j.prp.2025.156036_bib118","doi-asserted-by":"crossref","unstructured":"Coiffier, B., et al., A multicentre, phase II trial of ofatumumab monotherapy in relapsed\/progressive diffuse large B-cell lymphoma. 2013. 163(3): p. 334-342.","DOI":"10.1111\/bjh.12537"},{"key":"10.1016\/j.prp.2025.156036_bib119","doi-asserted-by":"crossref","unstructured":"Galanina, N., et al., Ofatumumab monotherapy in relapsed\/refractory diffuse large B-cell non-Hodgkin lymphoma. 2017. 58(3): p. 752-753.","DOI":"10.1080\/10428194.2016.1207764"},{"key":"10.1016\/j.prp.2025.156036_bib120","doi-asserted-by":"crossref","unstructured":"Morschhauser, F., et al., Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin's lymphoma: phase I\/II results. 2009. 27(20): p. 3346-3353.","DOI":"10.1200\/JCO.2008.19.9117"},{"key":"10.1016\/j.prp.2025.156036_bib121","doi-asserted-by":"crossref","unstructured":"Morschhauser, F., et al., Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. 2010. 21(9): p. 1870-1876.","DOI":"10.1093\/annonc\/mdq027"},{"key":"10.1016\/j.prp.2025.156036_bib122","doi-asserted-by":"crossref","unstructured":"Mahadevia, H., et al., A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas. 2024. 2(1): p. 10-24.","DOI":"10.3390\/lymphatics2010002"},{"key":"10.1016\/j.prp.2025.156036_bib123","doi-asserted-by":"crossref","unstructured":"Kunnumakkara, A.B., et al., Cancer drug development: The missing links. 2019. 244(8): p. 663-689.","DOI":"10.1177\/1535370219839163"},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib124","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156036_bib125","doi-asserted-by":"crossref","unstructured":"Sainatham, C., et al., The current socioeconomic and regulatory landscape of immune effector cell therapies. 2024. 11: p. 1462307.","DOI":"10.3389\/fmed.2024.1462307"},{"key":"10.1016\/j.prp.2025.156036_bib126","doi-asserted-by":"crossref","unstructured":"Garg, P., et al., Emerging therapeutic strategies to overcome drug resistance in cancer cells. 2024. 16(13): p. 2478.","DOI":"10.3390\/cancers16132478"},{"issue":"4","key":"10.1016\/j.prp.2025.156036_bib127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.prp.2025.156036_bib128","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156036_bib129","doi-asserted-by":"crossref","unstructured":"Hagenbeek, A., et al., Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. 2009. 114(22): p. 935.","DOI":"10.1182\/blood.V114.22.935.935"},{"issue":"8","key":"10.1016\/j.prp.2025.156036_bib130","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib131","first-page":"13","article-title":"Rituximab for follicular lymphoma","volume":"2","author":"Maloney","year":"2003","journal-title":"Curr. Hematol. Rep."},{"issue":"2","key":"10.1016\/j.prp.2025.156036_bib132","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrclinonc.2010.189","article-title":"Beyond chemotherapy: new agents for targeted treatment of lymphoma","volume":"8","author":"Younes","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib133","volume":"2","author":"Cho","year":"2023"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib134","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11899-021-00604-w","article-title":"A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine","volume":"16","author":"Epperla","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.prp.2025.156036_bib135","doi-asserted-by":"crossref","unstructured":"Hamadani, M., et al., Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma. 2018. 132: p. 928.","DOI":"10.1182\/blood-2018-99-118198"},{"key":"10.1016\/j.prp.2025.156036_bib136","doi-asserted-by":"crossref","unstructured":"Carlo-Stella, C., et al., S201: Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical hodgkin lymphoma (R\/R CHL). 2022. 6: p. 102-103.","DOI":"10.1097\/01.HS9.0000843696.37630.1c"},{"key":"10.1016\/j.prp.2025.156036_bib137","article-title":"LAG3's Enigmatic Mechanism of Action","volume":"11","author":"Graydon","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156036_bib138","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7545","article-title":"Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL) after anti\u2013PD-1 treatment: An open-label phase 1\/2 study","author":"Timmerman","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib139","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40164-022-00360-4","article-title":"Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches","volume":"11","author":"Hanel","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2025.156036_bib140","first-page":"1071","article-title":"Immunotherapy in Hodgkin lymphoma: present status and future strategies","volume":"11","author":"Vassilakopoulos","year":"2019"},{"issue":"1","key":"10.1016\/j.prp.2025.156036_bib141","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"15","key":"10.1016\/j.prp.2025.156036_bib142","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.prp.2025.156036_bib143","doi-asserted-by":"crossref","unstructured":"Trabolsi, A., A. Arumov, and J.H.J.Bcj Schatz, Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. 2024. 14(1): p. 27.","DOI":"10.1038\/s41408-024-00997-w"},{"key":"10.1016\/j.prp.2025.156036_bib144","doi-asserted-by":"crossref","unstructured":"Atwell, S., et al., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. 1997. 270(1): p. 26-35.","DOI":"10.1006\/jmbi.1997.1116"},{"key":"10.1016\/j.prp.2025.156036_bib145","series-title":"MAbs","article-title":"The use of CrossMAb technology for the generation of bi-and multispecific antibodies","author":"Klein","year":"2016"},{"key":"10.1016\/j.prp.2025.156036_bib146","doi-asserted-by":"crossref","unstructured":"Cassanello, G., A. Luna de Abia, and L.J.O. Falchi, Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma. 2024. 13(1): p. 2321648.","DOI":"10.1080\/2162402X.2024.2321648"},{"key":"10.1016\/j.prp.2025.156036_bib147","doi-asserted-by":"crossref","unstructured":"Kontermann, R.E. and U.J.Ddt Brinkmann, Bispecific antibodies. 2015. 20(7): p. 838-847.","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"10.1016\/j.prp.2025.156036_bib148","doi-asserted-by":"crossref","unstructured":"Falchi, L., S.A. Vardhana, and G.A.J.B. Salles, Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. 2023. 141(5): p. 467-480.","DOI":"10.1182\/blood.2021011994"},{"key":"10.1016\/j.prp.2025.156036_bib149","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., et al., Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. 2017. 376(9): p. 836-847.","DOI":"10.1056\/NEJMoa1609783"},{"issue":"2","key":"10.1016\/j.prp.2025.156036_bib150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/jpm15020051","article-title":"The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma","volume":"15","author":"Sun","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.prp.2025.156036_bib151","doi-asserted-by":"crossref","unstructured":"Lewis, K.L., C.Y.J.L. Cheah, and Lymphoma, The value of bispecific antibodies in relapsed and refractory DLBCL. 2024. 65(6): p. 720-735.","DOI":"10.1080\/10428194.2024.2323085"},{"key":"10.1016\/j.prp.2025.156036_bib152","doi-asserted-by":"crossref","unstructured":"Schlereth, B., et al., T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. 2006. 55: p. 503-514.","DOI":"10.1007\/s00262-005-0001-1"},{"key":"10.1016\/j.prp.2025.156036_bib153","doi-asserted-by":"crossref","unstructured":"Goebeler, M.-E., et al., Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. 2016. 34(10): p. 1104-1111.","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"10.1016\/j.prp.2025.156036_bib154","doi-asserted-by":"crossref","unstructured":"Viardot, A., et al., Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. 2016. 127(11): p. 1410-1416.","DOI":"10.1182\/blood-2015-06-651380"},{"issue":"11","key":"10.1016\/j.prp.2025.156036_bib155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17474086.2019.1676717","article-title":"Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma","volume":"12","author":"Bukhari","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.prp.2025.156036_bib156","doi-asserted-by":"crossref","unstructured":"Hutchings, M., et al., Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. 2021. 398(10306): p. 1157-1169.","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"10.1016\/j.prp.2025.156036_bib157","doi-asserted-by":"crossref","unstructured":"Thieblemont, C., et al., Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. 2023. 41(12): p. 2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"issue":"11","key":"10.1016\/j.prp.2025.156036_bib158","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"19","key":"10.1016\/j.prp.2025.156036_bib159","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"18","key":"10.1016\/j.prp.2025.156036_bib160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib161","doi-asserted-by":"crossref","unstructured":"Dickinson, M.J., et al., Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. 2022. 387(24): p. 2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"10.1016\/j.prp.2025.156036_bib162","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7550","article-title":"Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study","author":"Falchi","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib163","doi-asserted-by":"crossref","unstructured":"Zelenetz, A.D., et al., B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines. 2023. 21(11): p. 1118-1131.","DOI":"10.6004\/jnccn.2023.0057"},{"key":"10.1016\/j.prp.2025.156036_bib164","doi-asserted-by":"crossref","unstructured":"Ragoonanan, D., et al., Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. 2021. 18(7): p. 435-453.","DOI":"10.1038\/s41571-021-00474-4"},{"key":"10.1016\/j.prp.2025.156036_bib165","doi-asserted-by":"crossref","unstructured":"Klein, C., C. Jamois, and T.J.Eoobt Nielsen, Anti-CD20 treatment for B-cell malignancies: current status and future directions. 2021. 21(2): p. 161-181.","DOI":"10.1080\/14712598.2020.1822318"},{"key":"10.1016\/j.prp.2025.156036_bib166","doi-asserted-by":"crossref","unstructured":"Klebanoff, C.A., et al., Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. 2005. 26(2): p. 111-117.","DOI":"10.1016\/j.it.2004.12.003"},{"key":"10.1016\/j.prp.2025.156036_bib167","doi-asserted-by":"crossref","unstructured":"Gattinoni, L., et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+\u2009T cells. 2005. 202(7): p. 907-912.","DOI":"10.1084\/jem.20050732"},{"key":"10.1016\/j.prp.2025.156036_bib168","doi-asserted-by":"crossref","unstructured":"Hanel, W., et al., Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. 2022. 11(1): p. 108.","DOI":"10.1186\/s40164-022-00360-4"},{"key":"10.1016\/j.prp.2025.156036_bib169","doi-asserted-by":"crossref","unstructured":"Avanzi, M.P., et al., Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. 2018. 23(7): p. 2130-2141.","DOI":"10.1016\/j.celrep.2018.04.051"},{"key":"10.1016\/j.prp.2025.156036_bib170","doi-asserted-by":"crossref","unstructured":"Karsten, I.E., et al., Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs. 2024. 205(6): p. 2163-2174.","DOI":"10.1111\/bjh.19860"},{"key":"10.1016\/j.prp.2025.156036_bib171","doi-asserted-by":"crossref","unstructured":"Lefler, D.S., et al., Immunotherapy resistance in solid tumors: Mechanisms and potential solutions. 2024. 25(1): p. 2315655.","DOI":"10.1080\/15384047.2024.2315655"},{"key":"10.1016\/j.prp.2025.156036_bib172","doi-asserted-by":"crossref","unstructured":"Kordic, A., T.J. Phillips, and J.J.C. Weiss, The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. 2025. 17(7): p. 1192.","DOI":"10.3390\/cancers17071192"},{"key":"10.1016\/j.prp.2025.156036_bib173","doi-asserted-by":"crossref","unstructured":"Canelo-Vilaseca, M., et al., Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. 2025: p. 1-9.","DOI":"10.1038\/s41409-025-02539-9"},{"key":"10.1016\/j.prp.2025.156036_bib174","doi-asserted-by":"crossref","unstructured":"Looka, A., et al., A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. 2025. 9(3): p. 455-462.","DOI":"10.1182\/bloodadvances.2024012992"},{"key":"10.1016\/j.prp.2025.156036_bib175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.prp.2025.156036_bib176","doi-asserted-by":"crossref","DOI":"10.1002\/hon.85_2879","article-title":"efficacy and safety of tisagenlecleucel (tisa-cel) in adult patients (pts) with relapsed\/refractory follicular lymphoma (r\/r fl): primary analysis of the phase 2 elara trial","volume":"39","author":"Schuster","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156036_bib177","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2021-150721","article-title":"A propensity score-matched comparison of axi-cel and Tisa-cel for relapsed\/refractory diffuse large B-cell lymphoma in real-life: a lysa study from the descar-T registry","volume":"138","author":"Bachy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156036_bib178","doi-asserted-by":"crossref","unstructured":"Schuster, S.J., et al., Efficacy And Safety Of Tisagenlecleucel (Tisa-Cel) In Adult Patients (Pts) With Relapsed\/Refractory Follicular Lymphoma (R\/R Fl): Primary Analysis Of The Phase 2 Elara Trial. 2021.","DOI":"10.1002\/hon.85_2879"},{"key":"10.1016\/j.prp.2025.156036_bib179","doi-asserted-by":"crossref","unstructured":"Bachy, E., et al., A propensity score-matched comparison of axi-cel and tisa-cel for relapsed\/refractory diffuse large B-cell lymphoma in real-life: a Lysa Study from the Descar-T Registry. 2021. 138: p. 92.","DOI":"10.1182\/blood-2021-150721"},{"key":"10.1016\/j.prp.2025.156036_bib180","doi-asserted-by":"crossref","unstructured":"O'Leary, M.C., et al., FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. 2019. 25(4): p. 1142-1146.","DOI":"10.1158\/1078-0432.CCR-18-2035"},{"key":"10.1016\/j.prp.2025.156036_bib181","doi-asserted-by":"crossref","unstructured":"Crump, M., et al., Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. 2017. 130(16): p. 1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"10.1016\/j.prp.2025.156036_bib182","doi-asserted-by":"crossref","unstructured":"Schuster, S.J., et al., Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. 2019. 380(1): p. 45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"10.1016\/j.prp.2025.156036_bib183","doi-asserted-by":"crossref","unstructured":"Park, S., et al., Comparison of tisagenlecleucel with conventional treatments for relapsed\/refractory diffuse large B-cell lymphomas: a retrospective external comparator study. 2023. 13(1): p. 123.","DOI":"10.1038\/s41408-023-00889-5"},{"key":"10.1016\/j.prp.2025.156036_bib184","unstructured":"Ventola, C.L.J.P. and Therapeutics, Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations. 2017. 42(7): p. 452."},{"key":"10.1016\/j.prp.2025.156036_bib185","doi-asserted-by":"crossref","unstructured":"Patnaik, A., et al., Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors. 2015. 21(19): p. 4286-4293.","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"10.1016\/j.prp.2025.156036_bib186","doi-asserted-by":"crossref","unstructured":"Eun, Y., et al., Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. 2019. 9(1): p. 14039.","DOI":"10.1038\/s41598-019-50574-6"},{"key":"10.1016\/j.prp.2025.156036_bib187","doi-asserted-by":"crossref","unstructured":"Zheng, Y., et al., Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors. 2021. 26(11): p. e2002-e2012.","DOI":"10.1002\/onco.13918"},{"key":"10.1016\/j.prp.2025.156036_bib188","doi-asserted-by":"crossref","unstructured":"Dimou, M., et al., Pembrolizumab-induced remission after failure of axicabtagene ciloleucel: case report and literature review. 2021. 35(6): p. 3401-3406.","DOI":"10.21873\/invivo.12639"},{"key":"10.1016\/j.prp.2025.156036_bib189","doi-asserted-by":"crossref","unstructured":"Akl, I.B., et al., Current status and future perspectives of immunotherapy in middle-income countries: a single-center early experience. 2020. 11(4): p. 150.","DOI":"10.14740\/wjon1277"},{"issue":"3","key":"10.1016\/j.prp.2025.156036_bib190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2021.09.011","article-title":"Refractory DLBCL: Challenges and Treatment","volume":"22","author":"Goldfinger","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.prp.2025.156036_bib191","doi-asserted-by":"crossref","unstructured":"Blum, S.M., S.J. Rouhani, and R.J.J.Ir Sullivan, Effects of Immune-related adverse events (irAEs) and their treatment on antitumor immune responses. 2023. 318(1): p. 167-178.","DOI":"10.1111\/imr.13262"},{"key":"10.1016\/j.prp.2025.156036_bib192","doi-asserted-by":"crossref","unstructured":"Wang, D.-R., et al., Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. 2022. 7(1): p. 331.","DOI":"10.1038\/s41392-022-01136-2"},{"key":"10.1016\/j.prp.2025.156036_bib193","doi-asserted-by":"crossref","unstructured":"Hamadani, M., et al., Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. 2022. 6(3): p. 920-930.","DOI":"10.1182\/bloodadvances.2021005899"},{"key":"10.1016\/j.prp.2025.156036_bib194","doi-asserted-by":"crossref","unstructured":"Jantunen, E., E. Mahlam\u00e4ki, and T.J.Bmt Nousiainen, Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (\u2a7e 60 years) with non-Hodgkin\u2019s lymphoma: comparison with patients<\u200960 years treated within the same protocol. 2000. 26(7): p. 737-741.","DOI":"10.1038\/sj.bmt.1702577"},{"key":"10.1016\/j.prp.2025.156036_bib195","doi-asserted-by":"crossref","unstructured":"Bachanova, V., et al., Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. 2015. 50(2): p. 197-203.","DOI":"10.1038\/bmt.2014.259"},{"key":"10.1016\/j.prp.2025.156036_bib196","doi-asserted-by":"crossref","unstructured":"Kasamon, Y.L., et al., Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. 2015. 33(28): p. 3152-3161.","DOI":"10.1200\/JCO.2014.60.4777"},{"key":"10.1016\/j.prp.2025.156036_bib197","doi-asserted-by":"crossref","unstructured":"Van Besien, K., et al., Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. 2003. 102(10): p. 3521-3529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"10.1016\/j.prp.2025.156036_bib198","doi-asserted-by":"crossref","unstructured":"Schouten, H.C., et al., High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. 2003. 21(21): p. 3918-3927.","DOI":"10.1200\/JCO.2003.10.023"},{"issue":"17","key":"10.1016\/j.prp.2025.156036_bib199","first-page":"2093","article-title":"The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma","volume":"127","author":"Kuruvilla","year":"2016","journal-title":"J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.prp.2025.156036_bib200","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/febs.15750","article-title":"Clinical advances in targeting epigenetics for cancer therapy","volume":"289","author":"Feng","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.prp.2025.156036_bib201","doi-asserted-by":"crossref","unstructured":"Chen, I.-C., et al., Recent update of HDAC inhibitors in lymphoma. 2020. 8: p. 576391.","DOI":"10.3389\/fcell.2020.576391"},{"key":"10.1016\/j.prp.2025.156036_bib202","doi-asserted-by":"crossref","unstructured":"Zhang, Q., et al., Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas. 2019. 16(3): p. 424.","DOI":"10.7150\/ijms.30154"},{"key":"10.1016\/j.prp.2025.156036_bib203","doi-asserted-by":"crossref","unstructured":"Wang, L., et al., Advances in targeted therapy for malignant lymphoma. 2020. 5(1): p. 15.","DOI":"10.1038\/s41392-020-0113-2"},{"key":"10.1016\/j.prp.2025.156036_bib204","doi-asserted-by":"crossref","unstructured":"Ribeiro, M.L., et al., Epigenetic targets in B-and T-cell lymphomas: latest developments. 2023. 14: p. 20406207231173485.","DOI":"10.1177\/20406207231173485"},{"key":"10.1016\/j.prp.2025.156036_bib205","doi-asserted-by":"crossref","unstructured":"Ribatti, D., et al., The history of the angiogenic switch concept. 2007. 21(1): p. 44-52.","DOI":"10.1038\/sj.leu.2404402"},{"key":"10.1016\/j.prp.2025.156036_bib206","doi-asserted-by":"crossref","unstructured":"Ruan, J., et al., Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. 2009. 20(3): p. 413-424.","DOI":"10.1093\/annonc\/mdn666"},{"key":"10.1016\/j.prp.2025.156036_bib207","author":"Ruan","year":"2006","journal-title":"Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2025.156036_bib208","doi-asserted-by":"crossref","unstructured":"Wiernik, P., et al., Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory aggressive non-Hodgkin lymphoma. 2007. 25(18_suppl): p. 8052-8052.","DOI":"10.1200\/jco.2007.25.18_suppl.8052"},{"key":"10.1016\/j.prp.2025.156036_bib209","doi-asserted-by":"crossref","unstructured":"Witzig, T., et al., Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma. 2007. 25(18_suppl): p. 8066-8066.","DOI":"10.1200\/jco.2007.25.18_suppl.8066"},{"key":"10.1016\/j.prp.2025.156036_bib210","doi-asserted-by":"crossref","unstructured":"Ribatti, D., et al., Macrophages and angiogenesis in human lymphomas. 2024. 24(1): p. 26.","DOI":"10.1007\/s10238-023-01291-y"},{"key":"10.1016\/j.prp.2025.156036_bib211","doi-asserted-by":"crossref","unstructured":"Ilie, S., et al., Risk of infectious and non-infectious complications during the first cycle of chemotherapy in patients aged 65 or older: preliminary results from Institut Jules Bordet. 2013. 4: p. S83.","DOI":"10.1016\/j.jgo.2013.09.138"},{"key":"10.1016\/j.prp.2025.156036_bib212","doi-asserted-by":"crossref","unstructured":"Extermann, M., et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. 2012. 118(13): p. 3377-3386.","DOI":"10.1002\/cncr.26646"},{"key":"10.1016\/j.prp.2025.156036_bib213","doi-asserted-by":"crossref","unstructured":"Janssen-Heijnen, M.L., M. Extermann, and I.E.J.Crioh Boler, Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy? 2011. 79(1): p. 43-50.","DOI":"10.1016\/j.critrevonc.2010.07.001"},{"issue":"6","key":"10.1016\/j.prp.2025.156036_bib214","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2843","article-title":"The colony-stimulating factors and cancer","volume":"10","author":"Metcalf","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156036_bib215","doi-asserted-by":"crossref","unstructured":"Lyman, G., et al., Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. 2018. 29(9): p. 1903-1910.","DOI":"10.1093\/annonc\/mdy311"},{"key":"10.1016\/j.prp.2025.156036_bib216","unstructured":"Vanderpuye-Orgle, J., et al., Estimating the social value of G-CSF therapies in the United States. 2016. 22(10): p. e343-e349."},{"key":"10.1016\/j.prp.2025.156036_bib217","unstructured":"Silverstein, A.R., et al., The long-term social value of granulocyte colony-stimulating factors. 2019. 25(10): p. 486-493."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:31:37Z","timestamp":1749004297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825002298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":217,"alternative-id":["S0344033825002298"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156036","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156036"}}